Based on gene expression profiles of breast cancer, Ochiya et al. [32] revealed that RPN2 was involved in the treatment resistance of breast cancer and found that RPN2 was specifically expressed in ESA+/CD44+/CD24− breast cancer cells, which are considered “breast cancer stem cells”. Here, CD44 is linked to breast carcinoma.